Videos

Anas Younes, MD, chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, discusses current research for staging patients with follicular lymphoma. In order to design new clinical trials, researchers must have reliable predictors of overall survival and progression-free survival in patients.

Joaquim Bellmunt, MD, PhD, a medical oncologist at the Bladder Cancer Center at Dana-Farber Cancer Institute, discusses the updated results of the phase III KEYNOTE-045 trial after 2 years of follow-up. These updated results confirmed the primary findings of the study, which compared pembrolizumab (Keytruda) with investigator's choice of chemotherapy in patients with recurrent, advanced urothelial carcinoma.

Hossein Borghaei, DO, MS, chief of the Division of Thoracic Medical Oncology at Fox Chase Cancer Center, discusses biomarkers that may help identify patients with lung cancer who can benefit from immunotherapy agents. Since the introduction of these agents, PD-L1 has been used as a potential biomarker for selecting patients that may benefit from treatment. As PD-L1 is not completely reliable, there is interest in developing additional biomarkers.